Pharmaceutical Sector: Billion-Euro IPO Abandoned as Private Equity Takes Over Stada

In a significant development for the pharmaceutical industry, private equity firm Capvest has acquired a majority stake in the German drug manufacturer Stada. The acquisition was announced by Stada's current owners, Bain Capital and Cinven, who will retain a minority interest in the company. While financial specifics of the transaction remain undisclosed, reports from Bloomberg suggest the deal, including debt, is valued at around ten billion euros. Bain Capital's Michael Siefke noted that this successful exit underscores Stada's growth potential and the dedication of its workforce. Bain Capital and Cinven acquired Stada in 2017 for 5.3 billion euros, subsequently delisting the company. Since then, Stada has achieved impressive growth, boosting its revenue to over four billion euros and more than doubling its adjusted EBITDA, marking an annual growth rate of nine percent.

Market Analysis

Stada, known for brands like Grippostad and Ladival sunscreen, was anticipated to go public, with an IPO planned for the fall, depending on market conditions. CEO Peter Goldschmidt had indicated improved financial market stability as a favorable indicator for proceeding with the IPO. The public listing was expected to be one of the largest in Europe this year, potentially positioning Stada as a candidate for the MDax index. However, the IPO plans have now been scrapped, reflecting the challenges private equity firms face in realizing satisfactory valuations for their portfolio companies on the stock market. This move reiterates the reliance of private equity on public markets for profitable exits, a trend that has been difficult to navigate amid fluctuating market conditions. Stada itself has been burdened with approximately 5.7 billion euros in debt, partly due to a series of acquisitions. To enhance its appeal to investors, Stada divested its Russian operations, which had been seen as a hurdle in its sale plans. This strategic shift highlights the ongoing efforts to streamline operations and reduce exposure to volatile markets. The cancellation of Stada's IPO is a part of a broader trend, as illustrated by EY's IPO Barometer, which reported a 24 percent drop in European IPOs in the first half of this year, with total issuances reaching only 5.9 billion dollars compared to 14.7 billion the previous year.

Conclusion

The latest developments around Stada emphasize the intricate dynamics between private equity and public markets, showcasing the challenges in achieving desired financial outcomes through IPOs. As the pharmaceutical sector continues to evolve, the focus remains on strategic adaptations to navigate financial uncertainties and capitalize on growth opportunities.